HK1142535A1 - Methods of diagnosing and treating pre-eclampsia or eclampsia - Google Patents
Methods of diagnosing and treating pre-eclampsia or eclampsiaInfo
- Publication number
- HK1142535A1 HK1142535A1 HK10109057.9A HK10109057A HK1142535A1 HK 1142535 A1 HK1142535 A1 HK 1142535A1 HK 10109057 A HK10109057 A HK 10109057A HK 1142535 A1 HK1142535 A1 HK 1142535A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- eclampsia
- diagnosing
- methods
- treating pre
- treating
- Prior art date
Links
- 208000002296 eclampsia Diseases 0.000 title 1
- 201000011461 pre-eclampsia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- General Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/771,518 US7335362B2 (en) | 2002-07-19 | 2004-02-04 | Methods of treating pre-eclampsia or eclampsia |
US11/019,559 US7435419B2 (en) | 2002-07-19 | 2004-12-21 | Methods of diagnosing and treating pre-eclampsia or eclampsia |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1142535A1 true HK1142535A1 (en) | 2010-12-10 |
Family
ID=34859793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10109057.9A HK1142535A1 (en) | 2004-02-04 | 2010-09-22 | Methods of diagnosing and treating pre-eclampsia or eclampsia |
Country Status (11)
Country | Link |
---|---|
US (2) | US7435419B2 (xx) |
EP (2) | EP2172220B1 (xx) |
JP (1) | JP4711972B2 (xx) |
KR (1) | KR20070001991A (xx) |
CN (1) | CN1946423A (xx) |
AU (1) | AU2005213493A1 (xx) |
BR (1) | BRPI0507442B8 (xx) |
CA (1) | CA2554971A1 (xx) |
ES (1) | ES2404295T3 (xx) |
HK (1) | HK1142535A1 (xx) |
WO (1) | WO2005077007A2 (xx) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003265294B8 (en) * | 2002-07-19 | 2009-06-25 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
EP1773349A4 (en) * | 2004-05-04 | 2009-07-29 | Childrens Medical Center | METHODS AND COMPOSITIONS FOR TREATING PREECLAMPSIA |
ATE488251T1 (de) | 2004-09-24 | 2010-12-15 | Beth Israel Hospital | Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen |
US7740849B2 (en) * | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
WO2007053161A2 (en) | 2004-12-15 | 2007-05-10 | Beth Israel Deaconess Medical Center | Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy |
CA2602963A1 (en) * | 2005-03-24 | 2006-09-28 | Beth Israel Deaconess Medical Center | Methods of diagnosing fetal trisomy 13 or a risk of fetal trisomy 13 during pregnancy |
DE102005022047A1 (de) | 2005-05-09 | 2006-11-30 | Dade Behring Marburg Gmbh | Bindungspartner des Plazentalen Wachstumsfaktors insbesondere gegen den Plazentalen Wachstumsfaktor gerichtete Antikörper, ihre Herstellung und Verwendung |
US8329175B2 (en) * | 2005-08-26 | 2012-12-11 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders |
US20100190192A1 (en) * | 2005-09-15 | 2010-07-29 | Victor Voroteliak | Method of diagnosing pre-eclampsia |
US20070111326A1 (en) * | 2005-11-14 | 2007-05-17 | Abbott Laboratories | Diagnostic method for proteinaceous binding pairs, cardiovascular conditions and preeclampsia |
GB0600916D0 (en) * | 2006-01-17 | 2006-02-22 | Perkinelmer Instr Las Inc | detecting and predicting pre-eclampsia |
US20090286271A1 (en) * | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
US20080071151A1 (en) * | 2006-06-30 | 2008-03-20 | Sogin David C | Method and Apparatus for Diagnosing Pre-eclampsia |
US20090104649A1 (en) | 2007-06-11 | 2009-04-23 | Garovic Vesna D | Markers for preeclampsia |
WO2009083020A1 (en) | 2007-12-28 | 2009-07-09 | F. Hoffmann-La Roche Ag | Assessment of physiological conditions |
BRPI0907121A2 (pt) * | 2008-01-07 | 2015-07-14 | Ortho Clinical Diagnostics Inc | Calibrador/controle para ensaio simultâneo de proteínas capazes de se complexarem mutuamente |
JP2009162616A (ja) * | 2008-01-07 | 2009-07-23 | Univ Of Tokyo | オートタキシン測定による妊娠および妊娠高血圧症候群の検査方法および検査薬 |
CN101918839A (zh) * | 2008-01-07 | 2010-12-15 | 奥索临床诊断有限公司 | sFlt-1:血管生成因子络合物的测定 |
EP2120051B1 (en) * | 2008-05-13 | 2011-08-31 | Roche Diagnostics GmbH | Means and methods for predicting renal failure in diabetes patients based on placental growth factor and soluble FLT1 |
JP2011525241A (ja) * | 2008-06-18 | 2011-09-15 | アボット・ラボラトリーズ | PlGF−1コンパニオン診断方法および製品 |
CN104777308B (zh) * | 2008-10-31 | 2017-04-12 | 耶鲁大学 | 先兆子痫检测和治疗的方法和组合物 |
JP5753541B2 (ja) | 2009-12-21 | 2015-07-22 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 抗vegf治療によって治療された患者におけるタンパク尿の初期マーカー |
EP3248946B1 (en) | 2010-05-14 | 2021-02-24 | Beth Israel Deaconess Medical Center, Inc. | Extracorporeal devices and methods of treating complications of pregnancy |
MX339427B (es) * | 2010-07-19 | 2016-05-25 | Hoffmann La Roche | Biomarcadores de plasma de sangre para terapias de combinacion con bevacizumab para tratamiento de cancer pancreatico. |
CN105327347A (zh) * | 2010-07-19 | 2016-02-17 | 霍夫曼-拉罗奇有限公司 | 贝伐单抗组合疗法用于治疗乳腺癌的血浆生物标志物 |
GB201013151D0 (en) * | 2010-08-04 | 2010-09-22 | Isis Innovation | Diagnostic method |
KR101230740B1 (ko) * | 2010-09-08 | 2013-02-07 | 인제대학교 산학협력단 | 자간전증의 조기 진단 및 예후 평가 방법 |
JP6169495B2 (ja) | 2011-02-07 | 2017-07-26 | アガミン・エルエルシー | 妊娠関連高血圧性障害を治療または予防するための方法およびシステム |
WO2013068475A1 (en) * | 2011-11-09 | 2013-05-16 | Roche Diagnostics Gmbh | Dynamic of sflt-1 or endoglin/plgf ratio as an indicator for imminent preeclampsia and/or hellp syndrome |
WO2013106765A1 (en) | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
RU2483311C1 (ru) * | 2012-06-15 | 2013-05-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО РНИМУ им. Н.И. Пирогова Минздравсоцразви | Способ диагностики преэклампсии у беременных с хронической артериальной гипертензией |
BR112014029233A8 (pt) * | 2012-06-27 | 2019-01-29 | Hoffmann La Roche | método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio |
KR101297886B1 (ko) * | 2012-10-02 | 2013-08-19 | 인제대학교 산학협력단 | 자간전증의 조기 진단 및 예후 평가 방법 |
EP2965088B1 (en) | 2013-03-04 | 2018-12-05 | IQ Products B.V. | Prognostic marker to determine the risk for early-onset preeclampsia |
CN105917233B (zh) * | 2014-01-24 | 2018-07-03 | 豪夫迈·罗氏有限公司 | 产后hellp综合征、产后子痫或产后子痫前期的预测 |
CN107636466B (zh) * | 2015-02-18 | 2020-07-21 | 阿斯顿大学 | 先兆子痫的诊断性测定和治疗 |
MA41908A (fr) * | 2015-04-07 | 2021-03-31 | Shire Human Genetic Therapies | Anticorps anti-flt-1 utilisés dans le traitement de la dysplasie bronchopulmonaire |
US10711065B2 (en) * | 2015-04-07 | 2020-07-14 | Shire Human Genetic Therapies, Inc. | Anti-FLT-1 antibodies in treating bronchopulmonary dysplasia |
JP6840391B2 (ja) | 2015-06-19 | 2021-03-10 | セラ プログノスティックス, インコーポレイテッド | 早産を予測するためのバイオマーカーの対 |
WO2017149027A1 (en) * | 2016-03-01 | 2017-09-08 | Koninklijke Philips N.V. | Automated ultrasonic measurement of nuchal fold translucency |
WO2017189867A1 (en) * | 2016-04-27 | 2017-11-02 | Zietchick Research Institute, Llc | Method for monitoring fetus/preterm infant development, and for promoting the normal development of preterm infants |
WO2019036032A1 (en) | 2017-08-18 | 2019-02-21 | Sera Prognostics, Inc | PREGNANCY CLOCK PROTEINS FOR PREDICTING THE DATE AND MOMENT OF BIRTH |
CN111094988A (zh) | 2017-09-13 | 2020-05-01 | 普罗根尼蒂公司 | 先兆子痫生物标志物及相关系统和方法 |
GB201806042D0 (en) * | 2018-04-12 | 2018-05-30 | Univ Oxford Innovation Ltd | Biomarkers and uses thereof |
EP3880838A4 (en) * | 2018-11-15 | 2022-11-02 | The Board of Trustees of the Leland Stanford Junior University | COMPOSITIONS AND METHODS FOR PRODICTING AND CLASSIFICATION OF PREECLAMPIA |
AU2020221278A1 (en) * | 2019-02-14 | 2021-08-05 | Mirvie, Inc. | Methods and systems for determining a pregnancy-related state of a subject |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
WO2021113710A1 (en) * | 2019-12-04 | 2021-06-10 | Progenity, Inc. | Assessment of preeclampsia using assays for free and dissociated placental growth factor |
RU2717942C1 (ru) * | 2019-12-20 | 2020-03-27 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ диагностики преэклампсии по аминокислотному профилю плазмы крови |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
EP0338745B1 (en) | 1988-04-16 | 1995-03-01 | Celltech Limited | Method for producing recombinant DNA proteins |
US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
US5238819A (en) | 1988-12-14 | 1993-08-24 | The Regents Of The University Of California | Diagnostic assay for the detection of preeclampsia |
US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5219739A (en) | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
WO1993021319A1 (en) | 1992-04-08 | 1993-10-28 | Cetus Oncology Corporation | HUMANIZED C-erbB-2 SPECIFIC ANTIBODIES |
US5763441A (en) | 1992-11-13 | 1998-06-09 | Sugen, Inc. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5712395A (en) | 1992-11-13 | 1998-01-27 | Yissum Research Development Corp. | Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
US5895783A (en) * | 1993-07-16 | 1999-04-20 | Schering Aktiengesellschaft | Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor |
US6410322B1 (en) | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US5504074A (en) * | 1993-08-06 | 1996-04-02 | Children's Medical Center Corporation | Estrogenic compounds as anti-angiogenic agents |
US5861499A (en) | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
JPH10501681A (ja) | 1994-02-22 | 1998-02-17 | ダナ−ファーバー キャンサー インスティチュート | 核酸送達システムならびにその合成および使用方法 |
US5543138A (en) | 1994-03-10 | 1996-08-06 | Genetics Institute, Inc. | Methods of diagnosing and treating preeclampsia |
US6613757B1 (en) * | 1994-09-22 | 2003-09-02 | Board Of Regents, The University Of Texas System | Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy |
GB9512994D0 (en) | 1995-06-26 | 1995-08-30 | Brf International | Method for quantitative measurement of an enzyme linked immunosorbent assay |
US5830879A (en) | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
US6399585B1 (en) | 1996-05-15 | 2002-06-04 | Janet E. Larson | In Utero treatment of CFTR-related deficiencies |
WO1998028006A1 (en) | 1996-12-23 | 1998-07-02 | Cambridge University Technical Services Limited | Diagnosis and treatment of pathological pregnancies |
US20010056068A1 (en) * | 1998-03-04 | 2001-12-27 | Kristof Chwalisz | Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives |
US20030114407A1 (en) | 2001-12-06 | 2003-06-19 | Monia Brett P. | Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression |
US7030083B2 (en) | 1998-09-09 | 2006-04-18 | University Of Washington | Treatment of eclampsia and preeclampsia |
EP1417971A3 (en) | 1998-09-09 | 2004-06-30 | Scios Inc. | Use of an angiogenic factor for the treatment of microvascular angiopathies |
US6677300B1 (en) | 1998-09-09 | 2004-01-13 | Scios, Inc. | Treatment of microvascular angiopathies |
US6245577B1 (en) | 1998-09-11 | 2001-06-12 | Midland Bioproducts Corporation | IgG antibody testing method |
CN100349825C (zh) | 1998-09-28 | 2007-11-21 | 费伦顿有限公司 | 制备金刚石复合材料的方法及由该方法制备的复合材料 |
EP1016726A1 (en) | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
ATE450621T2 (de) | 2000-03-30 | 2009-12-15 | Whitehead Biomedical Inst | Mediatoren von rns-interferenz, die rns- sequenzspezifisch sind |
GB0008269D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Combination chemotherapy |
US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
GB0026823D0 (en) | 2000-11-02 | 2000-12-20 | King S College London | Diagnosis of pre-eclampsia |
WO2002070535A1 (en) | 2001-03-01 | 2002-09-12 | Isis Pharmaceuticals, Inc. | Antisense modulation of recql5 expression |
US7435419B2 (en) * | 2002-07-19 | 2008-10-14 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
AU2003265294B8 (en) | 2002-07-19 | 2009-06-25 | Beth Israel Deaconess Medical Center | Methods of diagnosing and treating pre-eclampsia or eclampsia |
US7335362B2 (en) | 2002-07-19 | 2008-02-26 | Beth Israel Deaconess Medical Center | Methods of treating pre-eclampsia or eclampsia |
US7323346B2 (en) | 2003-08-14 | 2008-01-29 | The General Hospital Corporation | Screening for gestational disorders |
CA2539430C (en) | 2003-09-23 | 2015-03-17 | The General Hospital Corporation | Screening for gestational disorders with sex hormone binding globulin as biomarker |
US7740849B2 (en) | 2004-09-24 | 2010-06-22 | Beth Israel Deaconess Medical Center | Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders |
US7727733B2 (en) * | 2004-12-21 | 2010-06-01 | Yale University | Diagnosis of preeclampsia |
US8787344B2 (en) | 2006-08-30 | 2014-07-22 | Qualcomm Incorporated | Method and apparatus for ACKCH with repetition in orthogonal systems |
US8349325B2 (en) | 2008-12-23 | 2013-01-08 | Abbott Laboratories | Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making |
-
2004
- 2004-12-21 US US11/019,559 patent/US7435419B2/en not_active Expired - Lifetime
-
2005
- 2005-02-04 CN CNA2005800121081A patent/CN1946423A/zh active Pending
- 2005-02-04 AU AU2005213493A patent/AU2005213493A1/en not_active Abandoned
- 2005-02-04 BR BRPI0507442A patent/BRPI0507442B8/pt active IP Right Grant
- 2005-02-04 EP EP09014672A patent/EP2172220B1/en active Active
- 2005-02-04 ES ES09014672T patent/ES2404295T3/es active Active
- 2005-02-04 JP JP2006552339A patent/JP4711972B2/ja active Active
- 2005-02-04 WO PCT/US2005/003884 patent/WO2005077007A2/en active Application Filing
- 2005-02-04 EP EP05722813A patent/EP1718334A4/en not_active Ceased
- 2005-02-04 CA CA002554971A patent/CA2554971A1/en not_active Abandoned
- 2005-02-04 KR KR1020067017827A patent/KR20070001991A/ko not_active Application Discontinuation
-
2008
- 2008-07-23 US US12/220,245 patent/US9518992B2/en active Active
-
2010
- 2010-09-22 HK HK10109057.9A patent/HK1142535A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP4711972B2 (ja) | 2011-06-29 |
CA2554971A1 (en) | 2005-08-25 |
AU2005213493A1 (en) | 2005-08-25 |
EP1718334A2 (en) | 2006-11-08 |
US20050170444A1 (en) | 2005-08-04 |
ES2404295T3 (es) | 2013-05-27 |
WO2005077007A2 (en) | 2005-08-25 |
BRPI0507442B8 (pt) | 2021-05-25 |
CN1946423A (zh) | 2007-04-11 |
BRPI0507442B1 (pt) | 2021-02-23 |
BRPI0507442A (pt) | 2007-07-10 |
KR20070001991A (ko) | 2007-01-04 |
US9518992B2 (en) | 2016-12-13 |
JP2007522457A (ja) | 2007-08-09 |
US20090117588A1 (en) | 2009-05-07 |
EP2172220B1 (en) | 2013-01-23 |
WO2005077007A3 (en) | 2006-03-16 |
EP1718334A4 (en) | 2008-04-23 |
EP2172220A1 (en) | 2010-04-07 |
US7435419B2 (en) | 2008-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1142535A1 (en) | Methods of diagnosing and treating pre-eclampsia or eclampsia | |
IL166393A0 (en) | Methods of diagnosing and treating pre-eclampsia or eclampsia | |
EP1756995A4 (en) | SYSTEM AND METHOD FOR REDUCING FRAUD | |
ZA200706787B (en) | Temperature prediction system and method | |
EP1721870A4 (en) | METHOD FOR NITRIFICATING AMMONIUM NITROGEN CONTAINING WATER AND TREATMENT METHOD THEREFOR | |
GB0520586D0 (en) | Wastewater treatment method and system | |
GB0705296D0 (en) | Lending system and method | |
GB0503449D0 (en) | Methods and systems using prediction of outcome for launched objects | |
EP1902145A4 (en) | METHOD FOR DIAGNOSIS AND TREATMENT OF AN INFLAMMATORY REACTION | |
ZA200608195B (en) | Improved configurations and methods for effluent gas treatment | |
EP1951908A4 (en) | METHODS RELATED TO DIAGNOSIS AND TREATMENT OF DEPRESSIONS | |
EP1884238A4 (en) | AGENTS WITH OBESITY ACTIVITY AND OBESITY INHIBITION PROCEDURE | |
EP1825044A4 (en) | BALLISTIC PLATE AND MANUFACTURING METHOD THEREFOR | |
EP2091551A4 (en) | METHOD FOR DIAGNOSING AND TREATING ASTHMA | |
EP1859826A4 (en) | CONTRAST REMOVAL SYSTEM AND METHOD FOR ACTIVATING THE CONTRAST REMOVAL SYSTEM | |
EP1888466A4 (en) | SYSTEM AND METHOD FOR TREATING WASTEWATER | |
GB0403600D0 (en) | Methods and reagents for treating disease | |
IL179557A0 (en) | Method of treating granuloma annulare or sarcoid | |
IL181541A0 (en) | Anoxic biological reduction system and method | |
EP1914315A4 (en) | METHOD FOR DETERMINING A GLYCOSYLATED PROTEIN AND DETERMINING KIT | |
EP1817847A4 (en) | SYSTEM AND METHOD FOR ECHO DELETION | |
IL186988A0 (en) | Epigenetic and genetic treatment method and system | |
EP2102228A4 (en) | METHOD FOR DIAGNOSIS OF PREECLAMPSIA | |
HK1133065A1 (en) | Refrigerant system and method of operating the refrigant system | |
EP1969548A4 (en) | DOCUMENT VERIFICATION SYSTEM AND METHOD OF USE |